C. Lévy

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort

M. Mouret-Reynier, O. Rigal, M. Chevrot, 2021, Breast Cancer Research and Treatment.

LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

M. Lacroix-Triki, N. Droin, V. Diéras, 2022, Annals of Oncology.

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.

V. Diéras, F. Dalenc, M. Chevrot, 2021, European journal of cancer.

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).

J. Lemonnier, B. Thürlimann, H. Hawle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1551O Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study

C. Coutant, A. Di Meglio, B. Pistilli, 2022, Annals of Oncology.

213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)

G. MacGrogan, H. Bonnefoi, O. Trédan, 2022, Annals of Oncology.

291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting

V. D’Hondt, V. Diéras, A. Gonçalves, 2021, Annals of Oncology.

Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort.

S. Michiels, C. Coutant, P. Arveux, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

T. Whelan, S. Aparicio, K. Gelmon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.